Avenzo Therapeutics
Developing next-generation oncology therapies for cancer patients.
Company facts
- Founded
- 2022
- Employees
- 125
- Headquarters
- United States
- CEO
- Athena Countouriotis
- Type
- Private
- Funding
- Series B · $60M · 2025
About
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company was co-founded in 2022 by Dr. Athena Countouriotis and Dr. Mohammad Hirmand, former CEO and CMO of Turning Point Therapeutics respectively. Headquartered in San Diego, California, Avenzo is dedicated to improving the lives of people diagnosed with cancer by delivering therapies that improve upon today's standard of care. The company is advancing a pipeline of potentially differentiated targeted oncology programs, including CDK2 and CDK4 inhibitors for hormone receptor-positive breast cancer, as well as bispecific antibody-drug conjugates targeting EGFR/HER3 and Nectin4/TROP2 for various solid tumors. Avenzo's approach leverages deep expertise in oncology drug development, with the resources, knowledge, and determination to advance drug candidates that address cancers with high unmet medical needs. The company has raised significant funding, including a $150 million oversubscribed Series A round and a $60 million Series B financing, demonstrating strong investor confidence in their mission and pipeline.
Open positions
Human Resources Generalist
Job Title: Human Resources Generalist Location: San Diego Job Type: Full-Time Who We Are Avenzo Therapeutics, Inc. (“ Avenzo ” or “ Company ”) is a clinical-stage biotechnology Company focused on developing…